Oral IL23 Receptor Blocker Meets Phase 3 Psoriasis Endpoints

Company Johnson & Johnson Innovative Medicine Event Type Phase 3 data disclosure (ICONIC-ASCEND) Modality Oral peptide Asset Icotrokinra Target IL-23 receptor Disease Area Moderate-to-severe plaque psoriasis Summary Johnson & Johnson disclosed November 6 Phase 3 ICONIC-ASCEND data for oral IL-23 receptor antagonist icotrokinra in moderate-to-severe…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *